ABO and Alzheimer disease: Because choroid plexus TNFR1 is also an important detrimental mediator in AD as was recently shown by the group, also the possibility to inhibit TNFR1 therapeutically with TROS was investigated in the acute AD model of icv oligomerized amyloid beta (AβO) injection.